Preparation of neoclerodane diterpenes as probes for the opioid receptor system
Anthony Lozama, Thomas E Prisinzano, David F. Wiemer, Jonathan A. Doorn, Horacio F. Olivo, Aliasger K. Salem, Michael W. Duffel
July 1, 2010 DOI: 10.17077/etd.57godcye (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Citations | 1 |
| Key points | Several salvinorin A analogues modified at C-2 and the furan ring retained affinity and efficacy at opioid receptors, indicating the furan ring is not required for opioid receptor activity. C-2 sulfonate analogues interacted differently from their ester counterparts. The authors argue these results show salvinorin A is amenable to chemical modification and has potential as a scaffold for developing opioid ligands. |
Abstract
While there are a variety of therapeutics that interact with the opioid receptor system, they are not without side effects; including constipation, dysphoria and respiratory depression. A better understanding of the opioid receptor system may yield therapeutic agents with a limited side effect profile. The neoclerodane diterpene, salvinorin A, appears to interact at opioid receptors through a unique mode of action. A better understanding of its interactions with opioid receptors will yield valuable information about the opioid system. In order to probe further how salvinorin A interacts at opioid receptors, a series of novel analogues modified at the C-2 and furan ring were synthesized and evaluated for their ability to interact at opioid receptors. Synthetic methods were identified to modulate the furan ring, including the synthesis of Diels-Alder cycloadducts and phenyl rings derived from a reductive elimination. The cycloadducts are one of the first reported examples of Diels-Alder chemistry being applied to modify a neoclerodane while the phenyl ring analogues are the first to have aromatic rings directly off the salvinorin A core. C-2 sulfonate analogues were found to interact differently then their ester counterparts at opioid receptors while several of the cycloadduct analogues maintained affinity and efficacy demonstrating the furan is not required for opioid receptor activity. These findings demonstrate that salvinorin A is amenable for chemical modification, illustrating its potential as a novel scaffold for the development of opioid ligands.
Citations in the library
Cites 58
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics March 1, 2004
- Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). Journal of Ethnopharmacology May 1, 1983
- Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. Journal of Psychoactive Drugs 1994
- Potential anxiolytic‐ and antidepressant‐like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents British Journal of Pharmacology May 5, 2009
and 53 more in the library